However, current evidence does not support the gap in treatment options for them. Unfortunately, age remains a key predictor of how patients are treated. Substantial errors of omission and commission affect the quality of geriatric cancer care. Dr. Silliman cited several recent studies to support her position. Older patients have similar biological responses to treatment as young cancer patients, older cancer patients generally tolerate treatment as well as younger patients, and older patients' treatment preferences are similar to those of younger patients.
Chronological age is a weak predictor of toxicity response.
A thorough assessment of overall comorbidity burden and composition of burden, functional status, cognitive function, mood, and social support is needed to optimize treatment decision making and follow-up care, including rehabilitation. Dr. Silliman suggested that key means of overcoming the treatment gap include thorough assessment and care integration. Elicit older patients' goals, concerns, and fears. Since many older persons have a long future life expectancy, treatment decisions should be focused on the overall functional capability of the patient and patient preferences regarding quality of life. Treatment strategies based on a thorough evaluation of the older patient are more likely to be successful in terms of compliance and effectiveness.